Voyager Therapeutics, Inc. (VYGR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 9, 2026, announces the fourth quarter and full year 2025 financial results and corporate updates for Voyager Therapeutics, Inc. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol VYGR.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial data and operational updates.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, risk factors, and contingencies are referenced as being part of the press release (Exhibit 99.1). The 8-K itself states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for those specific statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2025 financial figures.
- Verify cash runway and liquidity position as detailed in the full press release.
- Confirm any updates to clinical trial timelines or regulatory milestones mentioned in the corporate updates.
- Check for any new risk factors or contingencies disclosed in the referenced exhibit.